Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cadonilimab + pulocimab + paclitaxel
- Development stage
- Unknown
- Lead developer
- Kangfang Sainuo Pharmaceutical
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
cadonilimab + pulocimab + paclitaxel is a combination regimen used in oncology clinical research. **Cadonilimab** is a bispecific monoclonal antibody targeting both PD-1 and CTLA-4, engineered as an immunotherapy to enhance anti-tumor immune responses. **Pulocimab** is a monoclonal antibody that targets LAG-3, another immune checkpoint, also designed for cancer immunotherapy. **Paclitaxel** is a chemotherapeutic agent that stabilizes microtubules, disrupting mitosis and causing cell death in rapidly dividing tumor cells[1][2][3]. This combination regimen is under development for solid tumor malignancies, aiming to synergistically block multiple immune checkpoints while directly targeting tumor cells with cytotoxic chemotherapy.
- Other names
- taxol
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)PDCD1 (Programmed cell death protein 1 receptor)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on cadonilimab + pulocimab + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cadonilimab + pulocimab + paclitaxel.